Related Experiment Video
Updated: May 4, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.8K
Summary
In metastatic renal cell carcinoma, pazopanib and sunitinib showed similar progression-free survival. Pazopanib, however, demonstrated superior quality-of-life outcomes for patients in this phase III trial.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) is an advanced form of kidney cancer.
- Treatment options for mRCC aim to improve survival and quality of life.
- Pazopanib and sunitinib are targeted therapies used in mRCC treatment.
Purpose of the Study:
- To compare the efficacy and quality of life associated with pazopanib versus sunitinib in patients with metastatic renal cell carcinoma.
- To evaluate progression-free survival (PFS) as a primary efficacy endpoint.
- To assess patient-reported quality of life (QoL) as a key secondary endpoint.
Main Methods:
- A phase III clinical trial was conducted involving patients with metastatic renal cell carcinoma.
- Patients were randomized to receive either pazopanib or sunitinib.
- Progression-free survival and quality-of-life indices were measured and compared between the two treatment arms.
Main Results:
- Pazopanib and sunitinib demonstrated comparable progression-free survival rates in patients with mRCC.
- Patients treated with pazopanib reported significantly higher quality-of-life scores compared to those treated with sunitinib.
- This suggests a potential benefit of pazopanib in terms of patient well-being.
Conclusions:
- Pazopanib and sunitinib offer similar efficacy in terms of progression-free survival for metastatic renal cell carcinoma.
- Pazopanib provides a better quality of life for patients with mRCC compared to sunitinib.
- These findings support considering pazopanib for patients with mRCC where quality of life is a significant factor.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
4.2K
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
2.6K
Related Concept Videos
02:56Treatment Resistent Cancers
1.1K
1.1K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363